In Vitro Diagnostics (IVD) Quality Control Market Size (2025-2030)

The Global In Vitro Diagnostics (IVD) Quality Control Market was valued at USD 1.45 billion in 2024 and is projected to reach a market size of USD 2.21 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 7.3%. 

The In Vitro Diagnostics Quality Control Market represents the silent, indispensable guardian of clinical decision-making and the unseen backbone of the global healthcare system. It is the critical infrastructure of trust that underpins every blood test, tissue analysis, and molecular assay performed worldwide. In an industry where a single erroneous result can lead to misdiagnosis, improper treatment, and profound patient impact, this market provides the essential tools and processes to ensure that diagnostic tests are not just fast, but unfailingly accurate and reliable. IVD quality control (QC) is not a product but a rigorous discipline; it involves the use of specialized materials (controls and calibrators) with known properties to continuously verify the performance of diagnostic analysers, reagents, and laboratory procedures. It is the scientific method applied relentlessly, a constant process of checks and balances that transforms diagnostic testing from an art into a precise, reproducible science. The current market landscape is undergoing a significant metamorphosis, evolving from a simple compliance necessity into a sophisticated, data-driven pillar of laboratory management. For decades, QC was often reliant on instrument-specific controls provided by the original equipment manufacturer (OEM). Today, the market is pivoting decisively towards independent, third-party QC products. These unbiased materials, often designed to be used across multiple instrument platforms, provide laboratories with an objective assessment of their analytical performance, free from any potential manufacturer bias. This shift is being supercharged by the increasing complexity of diagnostics itself. This provides an unprecedented level of quality assurance, enabling labs to detect subtle performance shifts and identify potential issues long before they impact patient results. The long-term vision for the market is one of predictive, AI-driven quality assurance, where intelligent systems can anticipate instrument drift, optimize QC schedules, and create a truly resilient and fail-safe diagnostic environment. 

Key Market Insights: 

• As the core IVD testing space becomes increasingly commoditized, players must lean into digital diagnostics (analytics, decision support, remote monitoring) to capture incremental value beyond just assay hardware. McKinsey notes that adjacent digital markets such as clinical decision support and population health management are projected to outpace core diagnostics growth, thereby offering a growth pathway for IVD firms that embed quality control and analytics into their offerings. 
• The market for molecular diagnostics quality controls saw a 25% year-over-year increase in demand in 2024, with over 40% of this growth attributed specifically to the need for multiplex controls for respiratory viral panels (including Influenza, RSV, and SARS-CoV-2). 
• An analysis of laboratory budgets in 2024 revealed that spending on quality control products and associated data management software accounted for approximately 3-5% of a typical high-volume laboratory's total operational expenditure. 
• Liquid, ready-to-use quality controls accounted for over 70% of total unit sales in 2024, as laboratories overwhelmingly preferred them over lyophilized (freeze-dried) controls to reduce preparation time and minimize potential human errors in reconstitution. 
• In 2024, participation in inter-laboratory peer comparison programs, which allow labs to benchmark their QC results against a global pool of users, grew by an estimated 15%, with over 50,000 laboratories globally participating in such programs. 
• The market for quality controls specifically designed for point-of-care testing (POCT) devices saw a 20% increase in 2024, driven by the decentralization of testing into clinics, pharmacies, and hospital wards, which requires simpler, more robust QC solutions. 
• An estimated 30% of all QC data in large laboratory networks in 2024 was managed through cloud-based software platforms, enabling real-time, centralized oversight of analytical performance across multiple sites. 

Market Drivers: 

The global healthcare landscape is governed by an increasingly stringent web of regulations and accreditation standards, such as ISO 15189, CLIA in the U.S., and CAP.  

These bodies are the primary driver compelling laboratories to move beyond basic QC and adopt more sophisticated quality assurance programs. Accreditation is no longer a choice but a necessity for reimbursement and professional standing. These standards explicitly require laboratories to use stable quality control materials, monitor performance over time, and participate in inter-laboratory comparison programs. This regulatory pressure forces continuous investment in high-quality QC products and data management systems, transforming them into a non-negotiable operational cost. 

The modern clinical laboratory is a highly automated environment, processing thousands of samples daily on complex, multi-analyte platforms.  

This dual trend of automation and complexity is a powerful driver for the IVD QC market. Automated analysers require liquid, ready-to-use, barcoded controls that can be loaded directly onto the instrument, minimizing manual intervention and error. Furthermore, as tests become more complex—from large immunoassay panels to next-generation sequencing—the need for sophisticated, multiplexed quality controls that can validate the entire analytical process becomes mission-critical, fueling demand for advanced and specialized QC products. 

Market Restraints and Challenges: 

The most significant restraint is the budget pressure faced by healthcare institutions globally. Quality control products, particularly premium third-party controls, are often viewed as a significant operational cost, leading smaller labs with tight budgets to opt for less expensive or OEM-provided solutions. Additionally, the development of appropriate and stable QC materials for highly novel and esoteric assays, such as those in gene therapy or for rare biomarkers, presents a considerable technical and commercial challenge for manufacturers. 

Market Opportunities: 

A monumental opportunity exists in the rapidly growing markets of Asia, Latin America, and Africa, where new laboratories are being established and existing ones are upgrading to meet international quality standards. There is also immense potential in developing specialized QC products for the burgeoning fields of personalized medicine, liquid biopsy, and companion diagnostics, which require highly specific and well-characterized controls. Furthermore, the integration of artificial intelligence (AI) into QC data analysis to predict instrument failure and optimize testing schedules represents a major frontier for value creation. 

IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET REPORT COVERAGE:

In Vitro Diagnostics (IVD) Quality Control Market Segmentation: 

In Vitro Diagnostics (IVD) Quality Control Market Segmentation by Product Type: 

• Controls (Quality Control Materials) 

• Calibrators 

• Data Management Solutions (Software) 

• Services (Inter-laboratory Comparison Programs) 

The fastest-growing segment is Data Management Solutions. The digitalization of the laboratory is driving explosive growth in this area. Cloud-based software that enables real-time data analysis, automated reporting, and participation in global peer-comparison programs is becoming indispensable for modern labs seeking to optimize efficiency and ensure compliance. 

The most dominant segment is Controls. As the core consumable product required for the daily verification of every test run on every instrument, quality control materials represent the largest and most foundational component of the market by a significant margin. They are an essential, non-negotiable expenditure for every clinical laboratory. 

In Vitro Diagnostics (IVD) Quality Control Market Segmentation by Application: 

• Immunoassay 

• Clinical Chemistry 

• Hematology 

• Molecular Diagnostics 

• Microbiology 

• Coagulation/Hemostasis 

The fastest-growing segment is Molecular Diagnostics. Fueled by the rise of personalized medicine, infectious disease surveillance (post-COVID), and the increasing use of PCR and NGS technologies, the need for precise and reliable quality controls for these highly sensitive and complex assays is expanding at an accelerated pace. 

The most dominant segment is Immunoassay. This application's dominance is driven by the immense volume of tests performed globally for a wide array of analytes, including hormones, infectious disease markers, cardiac markers, and tumor markers. Every one of these tests requires routine quality control, making it the largest end-use market. 

In Vitro Diagnostics (IVD) Quality Control Market Segmentation by Manufacturer Type: 

• IVD Instrument Manufacturers (OEM) 

• Third-Party QC Manufacturers 

The fastest-growing segment is Third-Party QC Manufacturers. Laboratories are increasingly seeking unbiased, independent controls that can be used across multiple different instrument platforms. This allows for a true, objective assessment of performance and simplifies QC inventory, driving a market shift towards specialized, independent providers. 

The most dominant segment is IVD Instrument Manufacturers (OEM). OEM-provided controls are often bundled with instrument purchases and are specifically optimized for that system. This convenience and built-in compatibility ensure that OEM controls, while facing growing competition, still command a dominant share of the market, particularly in closed-system environments. 

In Vitro Diagnostics (IVD) Quality Control Market Segmentation by End-User: 

• Hospitals 

• Clinical/Independent Laboratories 

• Academic & Research Institutes 

• Home Care/Self-Testing 

The fastest-growing segment is Clinical/Independent Laboratories. The ongoing trend of healthcare consolidation and the centralization of testing into large, high-throughput commercial laboratory networks is driving rapid growth in this segment. These large-scale labs are major consumers of third-party QC and advanced data management solutions. 

The most dominant segment is Hospitals. Hospital-based laboratories remain the primary site for diagnostic testing globally, handling everything from routine checks to critical emergency room diagnostics. The sheer volume and breadth of testing performed within hospital settings make them the largest and most established end-user group. 

In Vitro Diagnostics (IVD) Quality Control Market Segmentation: Regional Analysis: 

• North America 

• Europe 

• Asia-Pacific 

• Latin America 

• Middle East & Africa 

The most dominant region is North America, commanding an estimated market share of 42%. This is due to its highly developed healthcare infrastructure, stringent regulatory requirements (CLIA), high adoption of advanced diagnostic technologies, and the presence of major QC manufacturers, making it the most mature and largest market. 

The fastest-growing region is Asia-Pacific. Propelled by rising healthcare expenditure in countries like China and India, the rapid expansion and modernization of laboratory networks, and a growing awareness of the importance of quality standards, this region presents the most significant growth potential. 

In Vitro Diagnostics (IVD) Quality Control Market COVID-19 Impact Analysis: 

The COVID-19 pandemic placed an unprecedented, intense spotlight on the critical importance of diagnostic accuracy and reliability. It triggered a massive, short-term surge in demand for quality controls for SARS-CoV-2 molecular and serological assays. More profoundly, the crisis exposed weaknesses in laboratory quality assurance processes globally. This has led to a lasting, positive impact on the market, with a permanently heightened awareness and increased investment in robust, third-party QC protocols for infectious disease testing and overall laboratory preparedness. 

Latest Market News: 

• September 2025: Bio-Rad Laboratories, Inc. announced the launch of its new InteliQ line of ready-to-use, liquid quality controls for diabetes and immunology testing, featuring barcode-enabled vials for seamless integration with automated laboratory tracks. 

• July 2025: LGC Seracare received FDA clearance for its new Seraseq® cfDNA v3 Reference Material, a highly multiplexed quality control product designed to validate the performance of liquid biopsy assays used in cancer diagnostics. 

Latest Trends and Developments: 

A key trend is the development of highly commutable QC materials that are manufactured using a human matrix and are designed to behave exactly like patient samples, providing a more accurate assessment of test performance. The integration of QC data with Laboratory Information Systems (LIS) for automated, real-time quality rule evaluation is another major development. Furthermore, there is a strong push towards creating consolidated, multi-analyte controls that can be used to check dozens of different tests at once, improving laboratory efficiency. 

Key Players in the Market: 

1. Bio-Rad Laboratories, Inc. 
2. Randox Laboratories Ltd. 
3. LGC Limited 
4. Roche Diagnostics 
5. Abbott Laboratories 
6. Siemens Healthineers AG 
7. Thermo Fisher Scientific Inc. 
8. Danaher Corporation 
9. Techno-path Clinical Diagnostics 
10. QuidelOrtho Corporation